Tetra Bio-Pharma Inc. (TSX:TBP) (OTCQB:TBPMF) Chief Commercial Officer Steeve Néron tells Proactive the biotech has acquired the Canadian exclusive rights for Dronabinol Soft Gel capsules, cannabinoid derived prescription drug aimed to treat AIDS-related anorexia and severe nausea and vomiting associated with chemotherapy. Néron says the acquisition will allow Tetra to establish an immediate and direct commercial presence in Canada, adding to the group's top-line growth, giving it the capital to fuel its drug development program.
Tetra Bio-Pharma acquires Canadian rights to Dronabinol Soft Gel capsules, adding to top-line growth
Quick facts: Tetra Bio-Pharma
Price: 0.19 CAD
Market Cap: $53.55 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tetra Bio-Pharma named herein, including the promotion by the Company of Tetra Bio-Pharma in any Content on the Site, the Company receives from...FOR OUR FULL DISCLAIMER CLICK HERE